These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1475 related items for PubMed ID: 27167344

  • 1. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 2. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 14; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 3. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 14; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 4. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 14; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 5. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul 14; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 7. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z, Giacobbi AS, Louandre C, Sauzay C, Mammeri Y, Galmiche A.
    Cancer Lett; 2017 Apr 28; 392():1-8. PubMed ID: 28161506
    [Abstract] [Full Text] [Related]

  • 8. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.
    J Surg Res; 2013 Nov 28; 185(1):225-30. PubMed ID: 23769634
    [Abstract] [Full Text] [Related]

  • 9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 10. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
    Cui SX, Zhang YS, Chu JH, Song ZY, Qu XJ.
    Cell Physiol Biochem; 2015 Oct 06; 35(1):201-12. PubMed ID: 25591763
    [Abstract] [Full Text] [Related]

  • 11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 06; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 12. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
    Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J, Tian J.
    Tumour Biol; 2015 Mar 06; 36(3):2143-53. PubMed ID: 25398692
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.
    Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273
    [Abstract] [Full Text] [Related]

  • 14. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN, Lee SM, Kim JS, Hwang SG.
    Cancer Chemother Pharmacol; 2019 Oct 28; 84(4):809-817. PubMed ID: 31385002
    [Abstract] [Full Text] [Related]

  • 15. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Oct 28; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.
    World J Gastroenterol; 2011 Sep 14; 17(34):3922-32. PubMed ID: 22025881
    [Abstract] [Full Text] [Related]

  • 17. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 14; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 18. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S, Wang Q, Feng M, Li J, Guan Z, An D, Dong M, Peng Y, Kuerban K, Ye L.
    Appl Microbiol Biotechnol; 2017 Feb 14; 101(4):1535-1546. PubMed ID: 27807662
    [Abstract] [Full Text] [Related]

  • 19. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 14; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 20. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C.
    Gut; 2018 Jul 14; 67(7):1328-1341. PubMed ID: 29275358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.